micro-community-banner
Profile Image
  • Add Media
  • Saved

8mo
ADA 2025 Highlights: Obesity Therapies, Islet Cell Advances, and Oral GLP-1 Outcomes in T2D

At ADA 2025, Dr. Mark Atkinson (University of Florida Diabetes Institute) highlighted the systemic benefits of obesity-targeted therapies, including cardiometabolic and cognitive improvements, while noting concerns about implementation and potential muscle loss. Emerging advances in stem cell–derived islet transplantation for type 1 diabetes show promise in reducing insulin dependence. Dr. John Buse (University of North Carolina) presented SOUL trial data indicating that oral GLP-1 receptor agonist therapy reduced major adverse cardiovascular events—CV death, nonfatal MI, or stroke—by 14%, with additional reductions in limb complications in high-risk patients with type 2 diabetes.

Profile Image
  • Saved

8mo
Possible Involvement of Lysophospholipids in Severe Asthma as Novel Lipid Mediators - PubMed

Possible Involvement of Lysophospholipids in Severe Asthma as Novel Lipid Mediators - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40001485/

In severe asthma, symptoms are unstable despite intensive treatment based on high doses of inhaled corticosteroids and on-demand use of oral corticosteroids. Although, recently, various biological agents related to Th2...

 

Severe asthma remains poorly controlled despite current therapies. Lysophospholipids, acting independently of Type 2 inflammation, may drive corticosteroid resistance and airway dysfunction, offering promising new targets for precision asthma treatment.

Profile Image
  • Saved

9mo
Lipidomics and genomics in mental health: insights into major depressive disorder, bipolar disorder, schizophrenia, and obsessive-compulsive disorder - PubMed

Lipidomics and genomics in mental health: insights into major depressive disorder, bipolar disorder, schizophrenia, and obsessive-compulsive disorder - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40069786/

Lipid signatures in MDD, BD, and SCZ shed light on underlying processes. Further research is needed to validate biomarkers and refine their clinical applications in precision psychiatry.

 

This review links altered lipid profiles and lipid-related genes to major psychiatric disorders, highlighting shared biomarkers and pathways, with potential for advancing precision psychiatry and clinical biomarker development.

Profile Image
  • Saved

9mo
Involvement of a battery of investigated genes in lipid droplet pathophysiology and associated comorbidities - PubMed

Involvement of a battery of investigated genes in lipid droplet pathophysiology and associated comorbidities - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39329369/

Lipid droplets (LDs) are highly specialized energy storage organelles involved in the maintenance of lipid homoeostasis by regulating lipid flux within white adipose tissue (WAT). The physiological function of adipocytes...

 

This review examines gene mutations affecting lipid droplet metabolism in white adipose tissue, linking disrupted lipid homeostasis to lipodystrophies, insulin resistance, and metabolic dysfunction through altered lipid storage and regulation.

Profile Image
  • Saved

9mo
The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review - PubMed

The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39061866/

Non-alcoholic fatty liver disease (NAFLD) is a global public health problem that causes liver-related morbidity and mortality. It is also an independent risk factor for non-communicable diseases. In 2020, a...

 

Natural antioxidants show greater efficacy than synthetic ones in treating metabolic-associated fatty liver disease (MAFLD), with both human and animal studies highlighting the importance of balancing oxidative stress in therapy.

Profile Image